Novo Nordisk considers another facility; Lonza’s new CEO shares his priorities
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Novo Nordisk has secured land and planning permission in Denmark to...
View ArticleClik here to view.
AbbVie expects $8.7B Cerevel buy to close ‘as early as next week,’ new CEO says
AbbVie said Thursday that its highly anticipated acquisition of Cerevel Therapeutics is slated to close soon. It also reported higher-than-anticipated second-quarter revenues. The $8.7 billion deal,...
View ArticleGalderma deprioritizes study for IL-31 drug; UCB stops work in rare encephalitis
Plus, news about GlycoMimetics and Indivior: Galderma stops plans to develop nemolizumab in Phase 2: The Swiss dermatology company said it will “deprioritize” nemolizumab in advanced chronic kidney...
View ArticleSanofi shelves four assets, including mid-stage dwarfism candidate
Sanofi is deprioritizing a mid-stage treatment for a form of dwarfism and culling three other early-stage studies. The French pharma deprioritized a Phase 2 drug that it was testing to treat...
View ArticleClik here to view.
AstraZeneca details ‘very ambitious’ strategy for early-stage obesity programs
AstraZeneca plans to develop treatment options for people with different BMIs as part of its “very ambitious” obesity strategy. AstraZeneca CEO Pascal Soriot on Thursday detailed the company’s plans,...
View ArticleClik here to view.
AbbVie beats expectations with smaller Humira slide — and big gains for next...
Humira isn’t going anywhere yet. And its successors are coming along nicely, too. On Thursday, AbbVie shared second-quarter financial results that show its cornerstone immunology medication eroded more...
View ArticleClik here to view.
Taking advantage of recent successes, Roche will push obesity drugs faster,...
With GLP-1 drugs taking the pharma world by storm, Roche is attempting to push forward the drugs it acquired in its Carmot Therapeutics acquisition last year a little bit faster. The bid to accelerate...
View ArticleIpsen loses legal appeal over whether blockbuster cancer treatment is a drug...
The pharma company Ipsen has lost the latest round of its legal effort to have its blockbuster cancer product Somatuline Depot classified as a biologic, instead of a drug. Ipsen had sued after the FDA...
View ArticleClik here to view.
EU panel follows FDA’s lead on Wegovy, recommending use to prevent cardiac...
European regulators are poised to approve Novo Nordisk’s blockbuster drug Wegovy to reduce the risk of cardiovascular events in patients who are overweight or obese. The EU’s Committee for Medicinal...
View ArticleFDA advisors call for better studies of immunotherapy around lung cancer...
Pharma companies developing treatments for lung cancer should design more nuanced clinical trials that can provide better data about how the drugs are used in combination with surgery, a panel of...
View ArticleClik here to view.
Updated: With cost-cutting underway, Bristol Myers raises guidance, touts...
Bristol Myers Squibb reported a Phase 3 success and a pipeline cut as part of its second-quarter earnings Friday morning. The company said a pivotal trial for cendakimab, an anti-IL-13 monoclonal...
View ArticleClik here to view.
Westlake's non-opioid pain startup Latigo gets new leader; Ron Cooper lands...
Nima Farzan Nima Farzan has joined pain company Latigo Biotherapeutics after leaving Kinnate Biopharma, which was sold to XOMA Corporation in April. Latigo emerged earlier this year with $135 million...
View ArticleFDA approves Sun Pharma's JAK inhibitor Leqselvi for hair loss in adults
Sun Pharma’s $576 million acquisition of Concert Pharmaceuticals is paying off with an FDA approval of the alopecia drug that came with the 2023 deal. The agency approved the tablet Leqselvi...
View ArticleCalliditas claims mid-stage win for rare liver disease drug
Calliditas Therapeutics’ NOX enzyme inhibitor succeeded in a Phase 2b trial in people with a rare liver disease that features inflammation and injury in the bile ducts. In the placebo-controlled...
View ArticleEuropean drug regulator rejects Eisai and Biogen's Alzheimer's drug Leqembi,...
The European Medicines Agency on Friday held its ground against anti-amyloid treatments, saying it will not recommend Eisai and Biogen’s Alzheimer’s drug Leqembi for approval. The decision, according...
View ArticleProMIS announces PIPE up to $122M; Confo raises €60M in Series B
Plus, news about Innovent Biologics and Acticor: ProMIS Neurosciences inks $122.7M placement after sharing Alzheimer’s data: The biotech said its amyloid beta monoclonal antibody was safe and crossed...
View ArticleClik here to view.
Cue Biopharma prioritizes autoimmune pipeline, axes a quarter of staff to...
To extend its cash reserves, Cue Biopharma is shifting focus away from its oncology assets and will zero in on its autoimmune disease pipeline instead. The biotech is also slashing its workforce by...
View ArticleAndrew Left, Citron Research short seller who campaigned against Valeant, is...
For years, Andrew Left and his short-selling fund Citron Research were a swashbuckling presence on social media, accusing companies of fraud and misdeeds, and making stock bets that he was right. On...
View ArticleClik here to view.
Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout...
Bristol Myers Squibb has resumed recruitment for its lead radiopharmaceutical trial after an isotope shortage forced a pause earlier this year, chief medical officer Samit Hirawat said on the company’s...
View ArticlePfizer and BioNTech say GSK's Covid patent suit is 'groundless'
Pfizer and BioNTech have called GSK’s patent lawsuit “groundless,” accusing the British drugmaker of “improperly contorting” its claims to say their blockbuster Covid vaccine is covered by GSK patents....
View Article